Tillkännagivande • May 21
InMed Pharmaceuticals Inc. announced that it expects to receive $290 million in funding from a group of investors InMed Pharmaceuticals Inc. has announced to issue common shares for gross proceeds of $ 290,000,000 on May 19, 2026. The transaction includes new investor participation from Commodore Capital LP, Deep Track Capital, Janus Henderson Investors US LLC, a16z Bio + Health, Venrock Healthcare Capital Partners Fund, L.P., Wellington Management Group LLp, TCG Crossover Management LLC, Blackstone Multi-Asset Investing, BB Biotech AG, Farallon Capital Management L.L.C, RTW Investments, LP, Vivo Capital, Perceptive Advisors and other leading investment management firms. The transaction has received approval by the Board of Directors of both companies and is expected to close in the second half of 2026, subject to certain closing conditions, including, among others, approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission to register the securities to be issued in connection with the proposed and the satisfaction of other customary closing conditions. New Risk • May 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 40% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (40% average weekly change). Shareholders have been substantially diluted in the past year (270% increase in shares outstanding). Market cap is less than US$10m (US$3.04m market cap). Minor Risk Revenue is less than US$5m (US$4.9m revenue). Reported Earnings • May 11
Third quarter 2026 earnings released: US$0.69 loss per share (vs US$1.94 loss in 3Q 2025) Third quarter 2026 results: US$0.69 loss per share. Net loss: US$2.79m (loss widened 32% from 3Q 2025). Tillkännagivande • Mar 28
InMed Pharmaceuticals Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance InMed Pharmaceuticals Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC dated March 27, 2026, notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. The notice has no immediate impact on the listing of the Company's common shares, which will continue to trade on The Nasdaq Capital Market subject to the Company's continued compliance with the other listing requirements of The Nasdaq Capital Market. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance. To regain compliance, the closing bid price of the common shares of the Company must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. The common shares of the Company will continue to trade under the symbol "INM". The Company intends to monitor the closing share price for its common shares and explore available options to regain compliance. In the event the Company does not evidence compliance with the minimum bid price requirement during the 180-day grace period, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, to Nasdaq. If it appears to the staff of Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Company will not be entitled to an additional 180 calendar days grace period and Nasdaq will provide notice to the Company that its securities will be subject to delisting. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, it is expected that Nasdaq would notify the Company that its common shares are subject to delisting. If the Company is notified by Nasdaq that its securities are subject to delisting, the Company may appeal such determination to a Nasdaq Hearings Panel but the Company's securities would be automatically suspended from trading on Nasdaq pending the completion of the appeal process. There can be no assurance that any such appeal would be successful or that the Company would be able to evidence compliance with the terms of any extension that may be granted by the Panel. Tillkännagivande • Mar 23
InMed Pharmaceuticals Announces Positive Data From Human Brain Organoid Neuroinflammation Models Supporting The INM-901 Alzheimer'S Disease Program InMed Pharmaceuticals Inc. announced new preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. These studies, conducted in collaboration with Stem Pharm Inc. using their proprietary platform of human neuro-immune organoids, represent a key step in translating prior animal model results for INM-901 into a human-relevant system, helping to de-risk the INM-901 program ahead of a first-in-human clinical trial. The in vitro human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials. INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide and interferon-gamma; and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients. INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's lipopolysaccharide-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models. Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo lipopolysaccharide-induced neuroinflammation model. Provides supportive evidence of mechanistic translation from animal models to human tissue systems. The consistency of INM-901's anti-inflammatory effects across in vivo animal models, ex vivo systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions. Key datasets impacting anti-neuroinflammation to date: In a long-term mouse model mimicking Alzheimer's disease, INM-901 significantly reduced inflammatory biomarkers interferon-gamma, TNF-alpha, IL-1beta, KC-GRO, IL-2 and neurodegenerative marker neurofilament light chain. INM-901 significantly reduced inflammasome activation and multiple pro-inflammatory cytokines, including NLRP3, IL-1beta, IL-6, IL-2 and KC-GRO in an lipopolysaccharide-induced neuroinflammation ex vivo model, demonstrated anti-inflammatory effects independent of amyloid-beta or tau pathology. Reduction of neuroinflammation in 3D human brain organoid models of Alzheimer's disease. Next steps for the INM-901 program for Alzheimer's disease: Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Third Quarter 2026. Continue to execute on IND-enabling pharmacology and toxicology studies. Continued development and scale-up of drug substance and product manufacturing activities to support IND enabling studies and submission. Engage regulatory/clinical experts in neurodegenerative diseases to map out topline clinical design for first-in-human clinical trials for the INM-901. Subject to regulatory feedback and completion of IND-enabling activities, the company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027. Recent drug development efforts in Alzheimer's disease have largely focused on amyloid plaque and tau pathology, leading to the first disease-modifying therapies in recent years. However, increasing attention is being directed toward neuroinflammation as a key underlying driver of disease progression. Studies presented at the recent global Alzheimer's conferences highlighted the relationship between inflammatory biomarkers and the risk of Alzheimer's disease and other dementias, underscoring the growing importance of targeting inflammation. Current research has demonstrated significant progress in understanding disease mechanisms and clinical interventions, with inflammation emerging as a critical factor influencing long-term patient outcomes. As such, neuroinflammation is increasingly recognized as a strategic therapeutic target for next-generation Alzheimer's treatments. New Risk • Feb 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.4m free cash flow). Shareholders have been substantially diluted in the past year (237% increase in shares outstanding). Market cap is less than US$10m (US$3.62m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$4.5m revenue). Reported Earnings • Feb 13
Second quarter 2026 earnings released: US$0.72 loss per share (vs US$3.65 loss in 2Q 2025) Second quarter 2026 results: US$0.72 loss per share (improved from US$3.65 loss in 2Q 2025). Revenue: US$820.2k (down 26% from 2Q 2025). Net loss: US$2.03m (loss narrowed 21% from 2Q 2025). New Risk • Dec 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (451% increase in shares outstanding). Market cap is less than US$10m (US$4.75m market cap). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$4.8m revenue). Reported Earnings • Nov 09
First quarter 2026 earnings released: US$0.44 loss per share (vs US$2.71 loss in 1Q 2025) First quarter 2026 results: US$0.44 loss per share. Revenue: US$1.12m (down 11% from 1Q 2025). Net loss: US$1.73m (loss widened 2.9% from 1Q 2025). Tillkännagivande • Oct 17
InMed Pharmaceuticals Inc. Announces Board Changes InMed Pharmaceuticals Inc. announced the appointment of Mr. John Bathery to its Board of Directors, effective 16 October 2025 . Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 years in corporate development and strategic partnerships. He currently serves as Head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals, where he has overseen pipeline and commercial divestitures, global alliance management, and integration of corporate transactions. Over his career, he has led and closed transactions with financial terms exceeding $60 billion across M&A, licensing, divestments, and collaborations. Mr. Bathery's extensive background in evaluating preclinical and early-stage assets, structuring value-creating partnerships, and leading cross-functional global initiatives will be highly relevant as InMed advances both its INM-901 program for Alzheimer's disease and INM-089 program in Age-related Macular Degeneration toward clinical readiness and explores potential partnerships. Additionally, the Company announced that, due to increasing professional obligations, Mr. Bryan Baldasare has decided to not stand for re-election at the Company's December 18, 2025 Annual General Meeting. Tillkännagivande • Sep 24
InMed Pharmaceuticals Inc., Annual General Meeting, Dec 17, 2025 InMed Pharmaceuticals Inc., Annual General Meeting, Dec 17, 2025. Reported Earnings • Sep 23
Full year 2025 earnings released: US$8.36 loss per share (vs US$20.14 loss in FY 2024) Full year 2025 results: US$8.36 loss per share. Revenue: US$4.94m (up 7.5% from FY 2024). Net loss: US$8.16m (loss widened 6.3% from FY 2024). Tillkännagivande • Jun 27
InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding On June 27, 2025, InMed Pharmaceuticals closed the transaction. The company announced that it has issued 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of CAD 2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules for gross proceeds of CAD 5,000,001.643. Tillkännagivande • Jun 25
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 5.000002 million in funding InMed Pharmaceuticals Inc. announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of CAD 2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules for gross proceeds of CAD 5,000,001.643 on June 25, 2025. The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and, along with the common shares underlying the short-term preferred investment options sold in the offering, have not been registered under the Act or applicable state securities laws. The offering is expected to close on or about June 25, 2025, subject to the satisfaction of customary closing conditions. Reported Earnings • May 14
Third quarter 2025 earnings released: US$1.94 loss per share (vs US$3.58 loss in 3Q 2024) Third quarter 2025 results: US$1.94 loss per share. Revenue: US$1.26m (up 7.6% from 3Q 2024). Net loss: US$2.12m (loss widened 23% from 3Q 2024). Tillkännagivande • Feb 15
Inmed Pharmaceuticals Inc. Announces Board and Committee Changes InMed Pharmaceuticals Inc. (the “ Company”), the Company’s shareholders withheld the election of one nominee, Ms. Janet Grove, at the Company’s 2024 Annual General Meeting held on December 18, 2024 (the “ 2024 AGM”), from being appointed as a member of the Company’s Board of Directors (the “ Board”). As a result, Ms. Grove offered her resignation to the Board, and the Company’s Nominating & Governance Committee, in accordance with the Company’s Majority Voting Policy, considered her resignation and ultimately recommended to the Board to accept Ms. Grove’s resignation. On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee. The Board intends to initiate a search for an independent director to replace Ms. Grove as soon as reasonably practicable. In the interim, the Board will continue to operate with the remaining four directors, and each committee of the Board will be comprised of the three independent directors who were re-appointed for directorship at the 2024 AGM. The Board Chair will assume the role of Chair of the Nominating & Governance Committee. Ms. Grove’s resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. The Board Chair, Mr. Andy Hull will assume the role of Chair of the Nominating & Governance Committee. Reported Earnings • Feb 13
Second quarter 2025 earnings released: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024) Second quarter 2025 results: US$3.65 loss per share. Revenue: US$1.11m (down 10% from 2Q 2024). Net loss: US$2.58m (loss widened 74% from 2Q 2024). Tillkännagivande • Jan 22
InMed Pharmaceuticals Inc. Announces Positive Results from A Long-Term in Vivo Preclinical Alzheimer's Disease Study InMed Pharmaceuticals Inc. announced positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression. Results from the long-term study of INM-901 in a well-characterized Alzheimer's disease model demonstrated the following: Improved cytokine profile -. INM-901 treated groups showed a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines such as TNF-a, IL-1ss and INF-g. Cytokine networks, when deregulated, may contribute to tissue inflammation. Reduction in neurodegeneration biomarker -. INM-901 demonstrated a dose- dependent and statistically significant reduction in neurofilament light chain ('NfL') in the plasma for the high dose treated group. NfL is a protein that is released from neurons in response to injury or disease. NfL levels are used to assess cellular damage in neurodegenerative disease. Study supported by mRNA data. mRNA assessments showed a reduction of several key neuroinflammatory genes in the brain, such as GFAP, CD-33 and TLR-2, further supporting the overall results from the study. INM-901: Program Summary to date. INM-901 is a proprietary small molecule drug candidate for Alzheimer's disease with potentially multiple mechanisms of action. Key characteristics of INM-901 include: demonstrates reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer's disease; is a preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death; impacts the peroxisome proliferator-activated receptors ("PPARs"), which have been shown to play an important role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer's disease; can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, offering many potential advantages over routes of administration of the currently approved products; and demonstrates significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness in long-term preclinical behavioural studies. Reported Earnings • Nov 17
First quarter 2025 earnings released: US$2.71 loss per share (vs US$15.24 loss in 1Q 2024) First quarter 2025 results: US$2.71 loss per share (improved from US$15.24 loss in 1Q 2024). Revenue: US$1.26m (up 40% from 1Q 2024). Net loss: US$1.68m (loss narrowed 34% from 1Q 2024). Board Change • Nov 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 2 highly experienced directors. President, CEO & Director Eric Adams is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 22
InMed Pharmaceuticals Inc. Announces the Appointment of Dr. Barry Greenberg to Its Scientific Advisory Board InMed Pharmaceuticals Inc. announced the appointment of Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. Barry Greenberg is an Associate Professor in the Department of Neurology and Director of the
Alzheimer's Disease Translational Center at the Johns Hopkins University School of Medicine. Dr. Greenberg has been involved in Alzheimer's disease ("AD") research and drug discovery since 1985, holding a series of positions internationally in the US, Sweden and Canada. He was part of a drug discovery team at AstraZeneca leading over 50 individuals from eight departments. He later led the preclinical biology research program at Neurochem Inc. in Québec as Senior Director of Pharmacology. Dr. Greenberg moved to the University Health Network in Toronto in 2008, as Director of Neuroscience Drug Discovery and Development, where he was responsible for the conceptualization and leadership as Strategy Director of the Toronto Dementia Research Alliance, a collaborative alliance across five research institutes. Additionally, he served as Chair of the National Institute on Aging's international committee, which was charged with strategizing the future structure of the Alzheimer's Disease Research Center ("ADRC") network. Dr. Greenberg moved to Johns Hopkins in 2018 to lead the development of an AD Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent AD at its earliest stages. He has been involved with the Johns Hopkins ADRC since that time, as a member of its Executive Committee and Co-Leader of its Research Education Component. He serves on several committees and advisory boards for NIA-funded initiatives focused on genetics, model development and clinical trials in AD, and is Editor-in-Chief of the journal "Alzheimer's & Dementia: Translational Research and Clinical Interventions". New Risk • Oct 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.0m free cash flow). Share price has been highly volatile over the past 3 months (56% average weekly change). Shareholders have been substantially diluted in the past year (168% increase in shares outstanding). Market cap is less than US$10m (US$2.11m market cap). Minor Risk Revenue is less than US$5m (US$4.6m revenue). Reported Earnings • Oct 01
Full year 2024 earnings released: US$1.01 loss per share (vs US$3.25 loss in FY 2023) Full year 2024 results: US$1.01 loss per share (improved from US$3.25 loss in FY 2023). Revenue: US$4.60m (up 11% from FY 2023). Net loss: US$7.68m (loss narrowed 3.4% from FY 2023). Tillkännagivande • Sep 27
InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024 InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024. Tillkännagivande • Jun 28
InMed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $1.03019 million. InMed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $1.03019 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • May 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Earnings have declined by 2.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Market cap is less than US$10m (US$1.62m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • May 15
Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.60 loss in 3Q 2023) Third quarter 2024 results: US$0.18 loss per share (improved from US$0.60 loss in 3Q 2023). Revenue: US$1.17m (up 13% from 3Q 2023). Net loss: US$1.72m (loss narrowed 14% from 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Apr 05
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease InMed Pharmaceuticals Inc. announced additional preclinical data demonstrating INM-901's positive pharmacological effects in the potential treatment of Alzheimer's disease ("AD"). The recent results demonstrating pharmacological effects in vivo disease models continue to validate INM-901 as a potential treatment of AD. The development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis. Several preclinical studies were conducted in well-characterized AD models. A summary of recent INM-901 preclinical study results includes: INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and impacts the PPAR signaling pathway. INM-901 demonstrates reduced neuroinflammation and improved neuronal function. INM-901 mRNA data supports the observations made in the previously released behavior studies in locomotor activity, cognition and memory. Previous studies of INM-901 showed the potential to target several biological pathways associated with AD, including neuroprotection to the differentiated neuronal cells from beta-amyloid peptide-induced toxicity and improvement of neuronal function via extension of neurite length, a potential breakthrough in the treatment of AD. The role of CB1, CB2 and PPAR in the treatment of Alzheimer's. CB1 and CB2 receptors are both part of the endocannabinoid system and are found throughout the body, including in the brain. CB1 receptors are primarily located in the central nervous system, particularly in areas involved in memory, cognition and motor function, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Activation of CB1 and CB2 receptors has been shown to have neuroprotective effects, meaning they can help protect brain cells from damage and death. In AD, where neuronal death is a hallmark feature, enhancing the activity of these receptors may help to slow down the progression of the disease. Activation of these receptors and other cellular receptors has also been shown to have an impact on neuroinflammation. As neuroinflammation is also believed to contribute to the progression of AD, targeting these receptors could help alleviate this inflammatory response. Several large pharmaceutical companies such as Eli Lilly, Roche, AbbVie, Eisai and Biogen lead research and commercialization efforts in AD drug development. Reported Earnings • Feb 14
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023) Second quarter 2024 results: US$0.18 loss per share (improved from US$0.91 loss in 2Q 2023). Revenue: US$1.24m (up 164% from 2Q 2023). Net loss: US$1.48m (loss narrowed 30% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Nov 30
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089 InMed Pharmaceuticals Inc. announced the launch of INM-089, a Cannabinoid analog, to investigate its effects in the treatment of Age-related Macular Degeneration. INM-089 is the company's second ocular pharmaceutical program. Results from a study, conducted under a collaborative research agreement with leading cannabinoid expert Dr. Mauro Maccarrone at the Universita degli Studi dell'Aquila (Italy), demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, in this model, treatment with INM-089 also improved the thickness of the outer nuclear layer ("ONL") of the retina where the photoreceptors are located. Based on widely accepted ocular research, there is a very strong correlation between the thickness of the ONL, photoreceptor preservation and visual acuity. Several CBN analog structures were screened in vitro and in vivo models to select the most appropriate candidate for continued development. InMed selected a specific CBN analog that outperformed its natural cannabinoid counterpart and demonstrated promising effects related to the treatment of AMD. From previous ocular research of the parent, naturally occurring cannabinoid CBN, the Company discovered its ability to proactively protect the nerve cells at the back of the eye in the retinal area, potentially preserving retinal function and vision in preclinical models. The results of this discovery led the Company to investigate optimization of the CBN molecule to better target AMD, resulting in the proprietary CBN analog, INM-089. AMD is the most common cause of vision loss and potential blindness in people over 50 years of age and globally affects about 35% of people 75 years and older. AMD affects the central vision, and the ability to see fine details. In AMD, a part of the retina called the macula is damaged. The two primary types of age-related macular degeneration are atrophic (non-exudative or "dry") AMD and neovascular (exudative or "wet") AMD. Wet AMD (approximately 10% of patients) is a more severe form of AMD and is characterized by neovascularization (i.e., development of excess vasculature), which can rapidly lead to blindness. In its early stages, AMD may have no signs or symptoms; therefore, most people do not know they have the disease until it is well developed. Currently, there is no cure for AMD; however, there are treatment options that may prevent or slow the progression of the disease. If AMD remains untreated, patients are likely to lose central field vision in the affected eye within 24 months of disease onset. InMed is developing a pipeline of rare cannabinoids and cannabinoid analogs across a spectrum of therapeutic applications with large unmet medical needs. pharmaceutical programs include a recently completed Phase 2 clinical trial studying the safety and efficacy of INM-755 cream for epidermolysis bullosa and preclinical programs in ocular and neurodegenerative diseases. Tillkännagivande • Nov 04
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 InMed Pharmaceuticals Inc. announced that an abstract describing the Phase 2 clinical study of investigational drug INM-755 Cannol ("CBN") cream for the treatment of symptoms in patients with epidermolysis bullosa ("EB"), a rare genetic skin disease, has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on November 5-7, 2023. The Phase 2 study was designed to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the study. The study used a within-patient, double-blind design whereby matched index areas were randomized to INM-755 CBN Cream or to control cream. The data showed a positive indication of enhanced anti-itch activity for INM-755 Cannol cream versus the control cream alone. Tillkännagivande • Oct 27
InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding On October 26, 2023, InMed Pharmaceuticals Inc. closed the transaction. Tillkännagivande • Oct 01
InMed Pharmaceuticals Inc. announced delayed annual 10-K filing On 09/29/2023, InMed Pharmaceuticals Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Sep 29
Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022) Full year 2023 results: US$3.25 loss per share (improved from US$33.17 loss in FY 2022). Revenue: US$4.14m (up 280% from FY 2022). Net loss: US$7.95m (loss narrowed 57% from FY 2022). Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Feb 11
InMed Pharmaceuticals Inc. announced delayed 10-Q filing On 02/10/2023, InMed Pharmaceuticals Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 29
InMed Pharmaceuticals Announces Voluntary Delisting from TSX InMed Pharmaceuticals Inc. announced that, based on the strong trading data on the Nasdaq, it has provided written notice to the Toronto Stock Exchange (the 'TSX') regarding the voluntary delisting of its common shares. InMed's common shares will continue to be listed and tradable on the Nasdaq under 'INM'. The Company believes that the trading volume of its shares on the TSX no longer justifies the expense and administrative efforts associated with maintaining this dual listing. InMed's listing on Nasdaq provides its shareholders with good liquidity, as Nasdaq has accounted for approximately 86% of its trading volume since its November 12, 2020 listing. The substantial savings in exchange fees, legal fees, and managerial time and effort to maintain a dual listing can be redirected into scientific programs, further advancing the business of the Company. InMed's common shares will continue to be listed and traded on Nasdaq and its Canadian shareholders' existing shares will trade through their brokers on the Nasdaq stock exchange. InMed anticipates that its common shares will be delisted from the TSX at the close of trading on or about May 7, 2021. Is New 90 Day High Low • Feb 12
New 90-day high: US$5.35 The company is up 59% from its price of US$3.37 on 13 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.